RESUMO
Third molar extraction is a common procedure frequently accompanied by moderate or severe pain, and involves sufficient numbers of patients to make studies relatively easy to perform. The aim of the present study was to determine the efficacy and safety of the therapeutic combination of 10 mg piroxicam, 1 mg dexamethasone, 35 mg orphenadrine citrate, and 2.5 mg cyanocobalamin (Rheumazin®) when compared with 20 mg piroxicam alone (Feldene®) in mandibular third molar surgery. Eighty patients scheduled for removal of the third molar were included in this randomized and double-blind study. They received (vo) Rheumazin or Feldene 30 min after tooth extraction and once daily for 4 consecutive days. Pain was determined by a visual analogue scale and by the need for escape analgesia (paracetamol). Facial swelling was evaluated with a measuring tape and adverse effects and patient satisfaction were recorded. There was no statistically significant difference in facial swelling between Rheumazin and Feldene (control group). Both drugs were equally effective in the control of pain, with Rheumazin displaying less adverse effects than Feldene. Therefore, Rheumazin appears to provide a better risk/benefit ratio in the mandibular molar surgery. Since the side effects resulting from nonsteroidal anti-inflammatory drug administration are a severe limitation to the routine use of these drugs in clinical practice, our results suggest that Rheumazin can be a good choice for third molar removal treatment.
Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Pessoa de Meia-Idade , Dexametasona/administração & dosagem , Dente Serotino/cirurgia , Orfenadrina/administração & dosagem , Piroxicam/administração & dosagem , Extração Dentária , /administração & dosagem , Anti-Inflamatórios/administração & dosagem , Anti-Inflamatórios/efeitos adversos , Método Duplo-Cego , Combinação de Medicamentos , Dexametasona/efeitos adversos , Edema/prevenção & controle , Relaxantes Musculares Centrais/administração & dosagem , Relaxantes Musculares Centrais/efeitos adversos , Orfenadrina/efeitos adversos , Medição da Dor , Estudos Prospectivos , Dor Pós-Operatória/tratamento farmacológico , Piroxicam/efeitos adversos , Índice de Gravidade de Doença , /efeitos adversos , Complexo Vitamínico B/administração & dosagem , Complexo Vitamínico B/efeitos adversosRESUMO
Infections of Plasmodium berghei in mice was stopped by azithromycin which was administered orally in dosages of 100mg/kg, for 28 days. This antibiotic was given since the same day that the animals were infected. The outcome suggests the necessity of more investigations on this antiparasitic activity.
A azitromicina debelou a infecção experimental de camundongos pelo Plasmodium berghei quando administrada, pela via oral e durante 28 dias, na dose de 100mg/kg, iniciada no mesmo dia em que os animais foram infectados. Mediante uso de 10mg/kg houve insucesso. Os resultados obtidos suscitam investigações complementares sobre a referida atividade antiparasitária desse medicamento.
Assuntos
Animais , Masculino , Camundongos , Antibacterianos/uso terapêutico , Azitromicina/uso terapêutico , Malária/tratamento farmacológico , Plasmodium berghei , Camundongos Endogâmicos BALB CRESUMO
Determina os parametros hematologicos: hemacias, hemoglobulina, hematocrito, indices hematimetricos, reticulocitos e hemossedimentacao, em 200 individuos adultos normais, residentes em Fortaleza, Ceara.Os valores encontrados foram submetidos a analise estatisca e os resultados comparados com os da literatura